Cargando…

Ongoing involvers and promising therapeutic targets of hepatic fibrosis: The hepatic immune microenvironment

Hepatic fibrosis is often secondary to chronic inflammatory liver injury. During the development of hepatic fibrosis, the damaged hepatocytes and activated hepatic stellate cells (HSCs) caused by the pathogenic injury could secrete a variety of cytokines and chemokines, which will chemotactic innate...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Nana, Yao, Huimin, Zhang, Zhixuan, Li, Zhuoqun, Chen, Xue, Zhao, Yan, Ju, Ran, He, Jiayi, Pan, Heli, Liu, Xiaoli, Lv, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978172/
https://www.ncbi.nlm.nih.gov/pubmed/36875101
http://dx.doi.org/10.3389/fimmu.2023.1131588
_version_ 1784899458795831296
author Zhang, Nana
Yao, Huimin
Zhang, Zhixuan
Li, Zhuoqun
Chen, Xue
Zhao, Yan
Ju, Ran
He, Jiayi
Pan, Heli
Liu, Xiaoli
Lv, Yi
author_facet Zhang, Nana
Yao, Huimin
Zhang, Zhixuan
Li, Zhuoqun
Chen, Xue
Zhao, Yan
Ju, Ran
He, Jiayi
Pan, Heli
Liu, Xiaoli
Lv, Yi
author_sort Zhang, Nana
collection PubMed
description Hepatic fibrosis is often secondary to chronic inflammatory liver injury. During the development of hepatic fibrosis, the damaged hepatocytes and activated hepatic stellate cells (HSCs) caused by the pathogenic injury could secrete a variety of cytokines and chemokines, which will chemotactic innate and adaptive immune cells of liver tissue and peripheral circulation infiltrating into the injury site, mediating the immune response against injury and promoting tissue reparation. However, the continuous release of persistent injurious stimulus-induced inflammatory cytokines will promote HSCs-mediated fibrous tissue hyperproliferation and excessive repair, which will cause hepatic fibrosis development and progression to cirrhosis even liver cancer. And the activated HSCs can secrete various cytokines and chemokines, which directly interact with immune cells and actively participate in liver disease progression. Therefore, analyzing the changes in local immune homeostasis caused by immune response under different pathological states will greatly enrich our understanding of liver diseases’ reversal, chronicity, progression, and even deterioration of liver cancer. In this review, we summarized the critical components of the hepatic immune microenvironment (HIME), different sub-type immune cells, and their released cytokines, according to their effect on the development of progression of hepatic fibrosis. And we also reviewed and analyzed the specific changes and the related mechanisms of the immune microenvironment in different chronic liver diseases.Moreover, we retrospectively analyzed whether the progression of hepatic fibrosis could be alleviated by modulating the HIME.We aimed to elucidate the pathogenesis of hepatic fibrosis and provide the possibility for exploring the therapeutic targets for hepatic fibrosis.
format Online
Article
Text
id pubmed-9978172
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99781722023-03-03 Ongoing involvers and promising therapeutic targets of hepatic fibrosis: The hepatic immune microenvironment Zhang, Nana Yao, Huimin Zhang, Zhixuan Li, Zhuoqun Chen, Xue Zhao, Yan Ju, Ran He, Jiayi Pan, Heli Liu, Xiaoli Lv, Yi Front Immunol Immunology Hepatic fibrosis is often secondary to chronic inflammatory liver injury. During the development of hepatic fibrosis, the damaged hepatocytes and activated hepatic stellate cells (HSCs) caused by the pathogenic injury could secrete a variety of cytokines and chemokines, which will chemotactic innate and adaptive immune cells of liver tissue and peripheral circulation infiltrating into the injury site, mediating the immune response against injury and promoting tissue reparation. However, the continuous release of persistent injurious stimulus-induced inflammatory cytokines will promote HSCs-mediated fibrous tissue hyperproliferation and excessive repair, which will cause hepatic fibrosis development and progression to cirrhosis even liver cancer. And the activated HSCs can secrete various cytokines and chemokines, which directly interact with immune cells and actively participate in liver disease progression. Therefore, analyzing the changes in local immune homeostasis caused by immune response under different pathological states will greatly enrich our understanding of liver diseases’ reversal, chronicity, progression, and even deterioration of liver cancer. In this review, we summarized the critical components of the hepatic immune microenvironment (HIME), different sub-type immune cells, and their released cytokines, according to their effect on the development of progression of hepatic fibrosis. And we also reviewed and analyzed the specific changes and the related mechanisms of the immune microenvironment in different chronic liver diseases.Moreover, we retrospectively analyzed whether the progression of hepatic fibrosis could be alleviated by modulating the HIME.We aimed to elucidate the pathogenesis of hepatic fibrosis and provide the possibility for exploring the therapeutic targets for hepatic fibrosis. Frontiers Media S.A. 2023-02-16 /pmc/articles/PMC9978172/ /pubmed/36875101 http://dx.doi.org/10.3389/fimmu.2023.1131588 Text en Copyright © 2023 Zhang, Yao, Zhang, Li, Chen, Zhao, Ju, He, Pan, Liu and Lv https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhang, Nana
Yao, Huimin
Zhang, Zhixuan
Li, Zhuoqun
Chen, Xue
Zhao, Yan
Ju, Ran
He, Jiayi
Pan, Heli
Liu, Xiaoli
Lv, Yi
Ongoing involvers and promising therapeutic targets of hepatic fibrosis: The hepatic immune microenvironment
title Ongoing involvers and promising therapeutic targets of hepatic fibrosis: The hepatic immune microenvironment
title_full Ongoing involvers and promising therapeutic targets of hepatic fibrosis: The hepatic immune microenvironment
title_fullStr Ongoing involvers and promising therapeutic targets of hepatic fibrosis: The hepatic immune microenvironment
title_full_unstemmed Ongoing involvers and promising therapeutic targets of hepatic fibrosis: The hepatic immune microenvironment
title_short Ongoing involvers and promising therapeutic targets of hepatic fibrosis: The hepatic immune microenvironment
title_sort ongoing involvers and promising therapeutic targets of hepatic fibrosis: the hepatic immune microenvironment
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978172/
https://www.ncbi.nlm.nih.gov/pubmed/36875101
http://dx.doi.org/10.3389/fimmu.2023.1131588
work_keys_str_mv AT zhangnana ongoinginvolversandpromisingtherapeutictargetsofhepaticfibrosisthehepaticimmunemicroenvironment
AT yaohuimin ongoinginvolversandpromisingtherapeutictargetsofhepaticfibrosisthehepaticimmunemicroenvironment
AT zhangzhixuan ongoinginvolversandpromisingtherapeutictargetsofhepaticfibrosisthehepaticimmunemicroenvironment
AT lizhuoqun ongoinginvolversandpromisingtherapeutictargetsofhepaticfibrosisthehepaticimmunemicroenvironment
AT chenxue ongoinginvolversandpromisingtherapeutictargetsofhepaticfibrosisthehepaticimmunemicroenvironment
AT zhaoyan ongoinginvolversandpromisingtherapeutictargetsofhepaticfibrosisthehepaticimmunemicroenvironment
AT juran ongoinginvolversandpromisingtherapeutictargetsofhepaticfibrosisthehepaticimmunemicroenvironment
AT hejiayi ongoinginvolversandpromisingtherapeutictargetsofhepaticfibrosisthehepaticimmunemicroenvironment
AT panheli ongoinginvolversandpromisingtherapeutictargetsofhepaticfibrosisthehepaticimmunemicroenvironment
AT liuxiaoli ongoinginvolversandpromisingtherapeutictargetsofhepaticfibrosisthehepaticimmunemicroenvironment
AT lvyi ongoinginvolversandpromisingtherapeutictargetsofhepaticfibrosisthehepaticimmunemicroenvironment